Comparative evaluation of warfarin utilisation in two primary healthcare clinics in the Cape Town area

Cardiovascular Journal of Africa

Volumn 24, Issue 2, 2013, Pages 19-23

  Njovane, Xolani W ^a   Fasinu, Pius S ^a   Rosenkranz, Bernd ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Anticoagulant; Drug monitoring; International normalised ratio; Warfarin; Warfarinisation

Indexed keywords

ANTIULCER AGENT; BETA LACTAM ANTIBIOTIC; NONSTEROID ANTIINFLAMMATORY AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; WARFARIN;

ADULT; AGE; ANTIBIOTIC THERAPY; ARTHRITIS; ARTICLE; COMORBIDITY; COMPARATIVE STUDY; DIABETES MELLITUS; DRUG INDICATION; DRUG UTILIZATION; FEMALE; GENDER; HEART ATRIUM FIBRILLATION; HOSPITAL; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; OBSTRUCTIVE AIRWAY DISEASE; PEPTIC ULCER; PRIMARY HEALTH CARE; RACE; RETROSPECTIVE STUDY; WEIGHT;

ADULT; ANTICOAGULANTS; CHI-SQUARE DISTRIBUTION; COMORBIDITY; DRUG INTERACTIONS; DRUG MONITORING; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; OUTPATIENT CLINICS, HOSPITAL; PHYSICIAN'S PRACTICE PATTERNS; POLYPHARMACY; PRIMARY HEALTH CARE; QUALITY INDICATORS, HEALTH CARE; RETROSPECTIVE STUDIES; SOUTH AFRICA; TREATMENT OUTCOME; WARFARIN;

EID: 84875892886     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: 10.5830/CVJA-2012-072     Document Type: Article

References (35)

1. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8-21s.
2. Chaves CJ, Caplan LR. Heparin and oral anticoagulants in the treatment of brain ischemia. J Neurol Sci 2000; 173: 3-9.
3. Lemos Silva R, Carvalho de Sousa J, Calisto C, Braz Nogueira JM, Ravara L. Oral anticoagulant therapy. Fundamentals, clinical practice and recommendations. Rev Port Cardiol 2007; 26: 769-788.
4. Hill CE, Duncan A. Overview of pharmacogenetics in anticoagulation therapy. Clin Lab Med 2008; 28: 513-524.
5. Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T, et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 2004; 103(7): 2630-2635.
6. Shek KL, Chan LN, Nutescu E. Warfarin-acetaminophen drug interaction revisited. Pharmacotherapy 1999; 19: 1153-1158.
7. Daly AK, Day PC, Guruprasad PA. CYP2C9 polymorphism and warfarin dose requirements. Br J Clin Pharmacol 2002; 53(4): 408-409.
8. Kealy C, Chen Z, Christie J, Thorn CF. Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity. Pharmacogenomics 2007; 8(3): 217-225.
9. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics 2007; 53: 99-111.
10. Le DT, Weibert RT, Sevilla BK, Donnelly KJ, Rapaport SI. The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods. Ann Intern Med 1994; 120: 552-558.
11. Gage BF, Fihn SD, White RH. Management and dosing of warfarin therapy. Am J Med 2000; 109: 481-488.
12. Odén A, Fahlén M. Oral anticoagulation and risk of death: a medical record linkage study. Br Med J 2002; 325: 1073-1075.
13. Srivastava A, Hudson M, Hamoud I, Cavalcante J, Pai C, Kaatz S. Examining warfarin underutilization rates in patients with atrial fibrillation: Detailed chart review essential to capture contraindications to warfarin therapy. Thromb J 2008; 6: 6.
14. Hirsh J, Dalen JE, Anderson DR, Poller L. Oral Anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S-21S.
15. Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, et al. Interindividual variability in sensitivity to warfarin - nature or nurture? Clin Pharmacol Ther 2001; 70: 159-164.
16. Miao L, Yang J, Huang C, Shen Z. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 2007; 63: 1135-1141.
17. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358: 999-1008.
18. Gong IY, Schwarz UI, Crown N, Dresser GK, Lazo-Langner A, Zou G, et al. Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. PLoS One 2011; 6(11): e27808.
19. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095-1106.
20. Tadros R, Shakib S. Warfarin - indications, risks and drug interactions. Aust Fam Physician 2010; 39: 476-479.
21. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011; 31: 326-343.
22. Sands CD, Chan ES, Welty TE. Revisiting the significance of warfarin protein-binding displacement interactions. Ann Pharmacother 2002; 36: 1642-1644.
23. Knijff-Dutmer EA, Schut GA, van de Laar MA. Concomitant coumarin-NSAID therapy and risk for bleeding. Ann Pharmacother 2003; 37(1): 12-16.
24. Davydov L, Yermolnik M, Cuni LJ. Warfarin and amoxicillin/clavulanate drug interaction. Ann Pharmacother 2003; 37: 367-370.
25. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007; 29: 687-710.
26. Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics J 2010; 11(6): 781-791.
27. Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH. Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomics 2007; 8(11): 1535-1544.
28. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics 2007; 7: 99-111
29. Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, Flockhart DA, et al. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European- Americans. Pharmacogenomics 2008; 9(10): 1445-1458.
30. Schelleman H, Brensinger CM, Chen J, Finkelman BS, Rieder MJ, Kimmel SE. New genetic variant that might improve warfarin dose prediction in African Americans. Br J Clin Pharmacol 2010; 70(3): 393-399.
31. Casimire T, Carter R, Peters S, Tweedle J, Charles KS. Establishing an oral anticoagulant monitoring service in a multiethnic developing country. Int J Lab Hematol 2008; 30(6): 531-535.
32. Suarez-Kurtz G, Botton MR. Pharmacogenomics of warfarin in populations of African descent. Br J Clin Pharmacol 2012 Jun 7. doi: 10.1111/j.1365-2125.2012. 04354.x. [Epub ahead of print]
33. Ramirez AH, Shi Y, Schildcrout JS, Delaney JT, Xu H, Oetjens MT, et al. Predicting warfarin dosage in European-Americans and African- Americans using DNA samples linked to an electronic health record. Pharmacogenomics 2012; 13(4): 407-418.
34. McLellan RA, Drobitch RK, Monshouwer M, Renton KW. Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metab Dispos 1996; 24: 1134-1138.
35. McMillin GA, Vazquez SR, Pendleton RC. Current challenges in personalizing warfarin therapy. Expert Rev Clin Pharmacol 2011; 4(3): 349-362.